MeiraGTx Holdings plc (MGTX)
Nasdaq · Biological Products, (No Diagnostic Substances) · Manufacturing · CIK 1735438 · fiscal year ends in Dec
Closing price $9.71 on 29 Oct 2026; 52-week range $6.99 to $14.97.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $397.5M
- Revenue growth
- 948.3%
- Net income, last twelve months
- $79.0M
- Earnings per share
- $0.71
- Operating margin
- 46.3%
- Net margin
- 19.9%
- Free cash flow
- $10.5M
- Return on equity
- 36.6%
- Market value
- $914.1M
- Price to earnings
- 13.7x
- Cash
- $143.2M
- Debt
- $100.0M
- Debt to equity
- 0.46
- Shares outstanding
- 94.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $81.4M | -$106.0M | -$114.2M | -$1.42 | -$50.2M | 10-K filed 30 Mar 2026 |
| FY2024 | 31 Dec 2024 | $33.3M | -$164.2M | -$147.8M | -$2.12 | -$109.5M | 10-K filed 13 Mar 2025 |
| FY2023 | 31 Dec 2023 | $14.0M | -$137.1M | -$84.0M | -$1.49 | -$125.5M | 10-K filed 13 Mar 2025 |
| FY2022 | 31 Dec 2022 | $15.9M | -$116.4M | -$129.6M | -$2.87 | -$118.1M | 10-K filed 14 Mar 2023 |
| FY2021 | 31 Dec 2021 | $37.7M | -$72.8M | -$79.6M | -$1.80 | -$56.9M | 10-K filed 10 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $321.4M | $160.7M | $1.71 |
| Q1 FY2026 | 31 Mar 2026 | $293.0K | -$46.3M | -$0.57 |
| Q4 FY2025 | 31 Dec 2025 | $75.4M | $15.1M | $0.19 |
| Q3 FY2025 | 30 Sep 2025 | $410.0K | -$50.5M | -$0.62 |
| Q2 FY2025 | 30 Jun 2025 | $3.7M | -$38.8M | -$0.48 |
| Q1 FY2025 | 31 Mar 2025 | $1.9M | -$40.0M | -$0.51 |
| Q4 FY2024 | 31 Dec 2024 | $21.4M | -$39.4M | -$0.49 |
| Q3 FY2024 | 30 Sep 2024 | $10.9M | -$39.3M | -$0.55 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| License revenue | $75.0M | 92.1% |
| Service revenue - related party | $6.4M | 7.9% |
Company events
The newest 8-K filings of 85 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 23 Sep 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 7 Jul 2026 | 8-K | Material agreement, Agreement ended, New debt, Share sale, Investor update | 1.01, 1.02, 2.03, 3.02, 7.01, 9.01 |
| 15 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 24 Apr 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 16 Apr 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 16 Apr 2026 | 8-K | Deal completed, Material agreement, Agreement ended, Investor update, Other events | 1.01, 1.02, 2.01, 7.01, 8.01, 9.01 |
| 16 Apr 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 26 Mar 2026 | 8-K | Results, Material agreement, New debt | 1.01, 2.02, 2.03, 9.01 |
| 2 Jan 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 187 held.
| Filed | Form | Period |
|---|---|---|
| 23 Sep 2026 | 8-K | 22 Sep 2026 |
| 13 Aug 2026 | S-8 | – |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 7 Jul 2026 | 8-K | 30 Jun 2026 |
| 15 Jun 2026 | 8-K | 11 Jun 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | DEF 14A | 11 Jun 2026 |
| 24 Apr 2026 | 8-K | 20 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 20 Oct 2026 | Giroux Richard, CFO & COO | Sale under a trading plan | 56,000 | $9.95 | $557.2K | 852,530 | 20 Oct 2026 |
| 6 Oct 2026 | Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY | Sale under a trading plan | 27,659 | $10.64 | $294.3K | 613,187 | 6 Oct 2026 |
| 18 Aug 2026 | Forbes Alexandria, PRESIDENT & CEO | Sale under a trading plan | 62,000 | $13.86 | $859.3K | 1,325,695 | 18 Aug 2026 |
| 21 Jul 2026 | Giroux Richard, CFO & COO | Sale under a trading plan | 56,000 | $12.51 | $700.6K | 908,530 | 21 Jul 2026 |
| 7 Jul 2026 | Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY | Sale under a trading plan | 2,547 | $13.86 | $35.3K | 665,958 | 7 Jul 2026 |
| 7 Jul 2026 | Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY | Sale under a trading plan | 25,112 | $14.90 | $374.2K | 640,846 | 7 Jul 2026 |
| 19 May 2026 | Forbes Alexandria, PRESIDENT & CEO | Sale under a trading plan | 62,000 | $9.17 | $568.5K | 1,387,695 | 19 May 2026 |
| 21 Apr 2026 | Giroux Richard, CFO & COO | Sale under a trading plan | 56,000 | $10.22 | $572.3K | 971,530 | 21 Apr 2026 |
| 7 Apr 2026 | Naylor Stuart, CHIEF DEV. OFFICER | Sale under a trading plan | 27,661 | $9.36 | $258.9K | 668,505 | 7 Apr 2026 |
| 24 Mar 2026 | Forbes Alexandria, PRESIDENT & CEO | Sale under a trading plan | 62,000 | $7.41 | $459.4K | 1,449,695 | 24 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 20 Oct 2026 | Richard Giroux, Officer | 56,000 | $557.2K | 20 Oct 2026 |
| 6 Oct 2026 | Naylor Stuart, Officer | 27,659 | $294.3K | 6 Oct 2026 |
| 18 Aug 2026 | Alexandria Forbes, Officer, Director | 62,000 | $859.3K | 18 Aug 2026 |
| 21 Jul 2026 | Richard Giroux, Officer | 56,000 | $700.6K | 21 Jul 2026 |
| 7 Jul 2026 | Naylor Stuart, Officer | 27,659 | $368.7K | 7 Jul 2026 |
| 19 May 2026 | Alexandria Forbes, Officer, Director | 62,000 | $568.5K | 19 May 2026 |
| 21 Apr 2026 | Richard Giroux, Officer | 56,000 | $572.5K | 21 Apr 2026 |
| 7 Apr 2026 | Naylor Stuart, Officer | 27,661 | $258.9K | 7 Apr 2026 |
| 24 Mar 2026 | Alexandria Forbes, Officer, Director | 62,000 | $459.4K | 24 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Rubric Capital Management LP | 13G amended | 9.83% | 9.1M |
| 13 May 2026 | Adage Capital Management, L.P. | 13G amended | 4.91% | 4.0M |
| 24 Apr 2026 | Perceptive Advisors LLC | 13D amended | 12.6% | 11.7M |
| 13 Feb 2026 | Prosight Management, LP | 13G amended | 4% | 3.2M |
| 13 Feb 2026 | Rubric Capital Management LP | 13G | 7.9% | 6.2M |
| 2 Jan 2026 | Perceptive Advisors LLC | 13D amended | 12.9% | 10.4M |
| 13 Nov 2025 | Adage Capital Management, L.P. | 13G amended | 5.2% | 4.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 6.4M | +7.37% | 6.51 |
| 30 Sep 2026 | 6.0M | +49.48% | 5.04 |
| 15 Sep 2026 | 4.0M | +7.75% | 6.08 |
| 31 Aug 2026 | 3.7M | -0.41% | 4.68 |
| 14 Aug 2026 | 3.7M | -4.08% | 8.07 |
| 31 Jul 2026 | 3.9M | -7.54% | 8.27 |
| 15 Jul 2026 | 4.2M | -10.63% | 3.66 |
| 30 Jun 2026 | 4.7M | -14.98% | 3.02 |
Funds that hold it
From each fund's latest Form 13F.
170 funds held it at 30 Jun 2026: 115 added and 22 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Sanofi | 12,197,737 | $164.8M | 0 |
| Perceptive Advisors LLC | 10,786,658 | $145.7M | +460,555 |
| Rubric Capital Management LP | 9,100,000 | $122.9M | +2,100,000 |
| Johnson & Johnson | 6,641,064 | $89.7M | 0 |
| BlackRock, Inc. | 4,757,178 | $64.3M | +1,589,030 |
| Adage Capital Partners GP, L.l.c. | 4,400,000 | $59.4M | +400,000 |
| Opaleye Management Inc. | 3,550,000 | $48.0M | +1,426,741 |
| Millennium Management LLC | 2,971,752 | $40.1M | -493,947 |
| 683 Capital Management, LLC | 2,300,000 | $31.1M | -150,000 |
| Woodline Partners LP | 1,500,135 | $20.3M | +1,199,812 |
Peers
Companies in the same industry.
- Amgen Inc. (AMGN): revenue $38.1B, market value $249.1B
- Gilead Sciences, Inc. (GILD): revenue $30.5B, market value $205.5B
- Moderna, Inc. (MRNA): revenue $2.2B, market value $88.9B
- argenx SE (ARGX): revenue $4.2B, market value $55.5B
- Biogen Inc. (BIIB): revenue $10.3B, market value $36.9B
- BioNTech SE (BNTX): revenue $3.2B, market value $22.4B
- Exelixis, Inc. (EXEL): revenue $2.5B, market value $16.2B
- Halozyme Therapeutics, Inc. (HALO): revenue $1.7B, market value $15.0B
- Neurocrine Biosciences Inc. (NBIX): revenue $3.4B, market value $14.9B
- Bio-Techne Corp. (TECH): revenue $1.2B, market value $11.3B